Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus
A Phase II Evaluation of DMAP Plus GM-CSF in the Treatment of Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus sargramostim in treating patients who have advanced, persistent, or recurrent cancer of the uterus.
研究概览
详细说明
OBJECTIVES:
- Determine the antitumor activity of dacarbazine, mitomycin, doxorubicin, and cisplatin plus sargramostim (GM-CSF) in patients with advanced, persistent, or recurrent leiomyosarcoma of the uterus.
- Determine the nature and degree of toxicity of this regimen in these patients.
OUTLINE: Patients receive dacarbazine IV over 2 hours, followed by mitomycin IV over 2-5 minutes, doxorubicin IV over 2-5 minutes, and cisplatin IV over 2 hours on day 1. Patients also receive sargramostim (GM-CSF) subcutaneously (SC) once every 12 hours on days -6 to -3 before the first chemotherapy course and then on days 2-15 and 23-26 of all chemotherapy courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease receive a maximum of 4 courses. Patients achieving complete or partial response receive a maximum of 6 courses.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 12-43 patients will be accrued for this study within 12-28 months.
研究类型
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Oslo、挪威、N-0310
- Norwegian Radium Hospital
-
-
-
-
California
-
Los Angeles、California、美国、90095-1781
- Jonsson Comprehensive Cancer Center, UCLA
-
-
Colorado
-
Denver、Colorado、美国、80010
- University of Colorado Cancer Center
-
-
District of Columbia
-
Washington、District of Columbia、美国、20307-5001
- Walter Reed Army Medical Center
-
-
Illinois
-
Chicago、Illinois、美国、60612-3864
- Rush-Presbyterian-St. Luke's Medical Center
-
-
Iowa
-
Iowa City、Iowa、美国、52242-1009
- Holden Comprehensive Cancer Center
-
-
Maryland
-
Bethesda、Maryland、美国、20892-1182
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
-
-
Massachusetts
-
Boston、Massachusetts、美国、02111
- Tuft-New England Medical Center
-
-
Minnesota
-
Rochester、Minnesota、美国、55905-0001
- Mayo Clinic Cancer Center
-
-
Missouri
-
Saint Louis、Missouri、美国、63110
- Washington University School of Medicine
-
-
New Jersey
-
Camden、New Jersey、美国、08103-1489
- Cooper University Hospital
-
-
New York
-
Stony Brook、New York、美国、11794-8091
- State University of New York Health Sciences Center - Stony Brook
-
-
North Carolina
-
Chapel Hill、North Carolina、美国、27599-7295
- Lineberger Comprehensive Cancer Center, UNC
-
Durham、North Carolina、美国、27710
- Duke Comprehensive Cancer Center
-
Winston-Salem、North Carolina、美国、27157-1065
- Comprehensive Cancer Center at Wake Forest University
-
-
Ohio
-
Cincinnati、Ohio、美国、45267-0526
- Barrett Cancer Center
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73190
- University of Oklahoma College of Medicine
-
-
Pennsylvania
-
Abington、Pennsylvania、美国、19001-3788
- Abington Memorial Hospital
-
Philadelphia、Pennsylvania、美国、19104-4283
- University of Pennsylvania Cancer Center
-
-
Texas
-
Galveston、Texas、美国、77555-0587
- University of Texas Medical Branch
-
-
Washington
-
Tacoma、Washington、美国、98405
- Tacoma General Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
DISEASE CHARACTERISTICS:
Histologically confirmed primary leiomyosarcoma (LMS) of the uterus
- Advanced, persistent, or recurrent disease that is refractory to curative therapy or established treatments
At least 1 unidimensionally measurable target lesion
- At least 20 mm by conventional techniques (e.g., palpation, plain x-ray, CT scan, or MRI) OR
- At least 10 mm by spiral CT scan
- Tumors within a previously irradiated field are designated as non-target lesions
- Ineligible for a higher priority Gynecologic Oncology Group protocol (if one exists), including any active phase III protocol for the same population
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- GOG 0-2
Life expectancy:
- Not specified
Hematopoietic:
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
Hepatic:
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- SGOT no greater than 2.5 times ULN
- Alkaline phosphatase no greater than 2.5 times ULN
Renal:
- Creatinine no greater than 1.5 times ULN
Other:
- No active infection requiring antibiotics
- No grade 2 or greater sensory or motor neuropathy
- No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- No prior cytotoxic chemotherapy for LMS of the uterus
Endocrine therapy:
- At least 1 week since prior hormonal therapy for LMS of the uterus
- Concurrent hormone replacement therapy allowed
Radiotherapy:
- See Disease Characteristics
- Recovered from prior recent radiotherapy
Surgery:
- Recovered from prior recent surgery
Other:
- Recovered from other prior recent therapy
- No prior cancer treatment that would preclude study therapy
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
合作者和调查者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.